The Korean journal of internal medicine

  • 제33권6호
  • /
  • Pages.1241-1251
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Systematic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases

  • Pyo, Junhee (WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Department of Pharmaceutical Science, Utrecht University) ;
  • Cho, Soo-Kyung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Kim, Dam (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Sung, Yoon-Kyoung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases)
  • 투고 : 2016.07.07
  • 심사 : 2016.11.16
  • 발행 : 2018.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: To estimate the level of agreement and positivity rates of latent tuberculosis infection (LTBI) tests prior to the use of tumor necrosis factor (TNF) inhibitors in relation to underlying rheumatic diseases and endemic tuberculosis levels. Methods: The Ovid-Medline, Embase, and Cochrane Libraries were searched for articles before October 2013 involving LTBI screening in rheumatic patients, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and psoriatic arthritis. Results: In pooled analyses, 5,224 rheumatic patients had undergone both a tuberculin skin test (TST) and an interferon-gamma release assay (IGRA) before TNF inhibitors use. The positivity of TST, QuantiFERON-TB Gold In Tube (QFT-GIT), and T-SPOT.TB (T-SPOT) tests were estimated to be 29%, 17%, and 18%, respectively. The agreement percentage between the TST and QFT-GIT, and between the TST and T-SPOT were 73% and 75%. Populations from low-to-moderate endemic TB presented with slightly less agreement (71% between TST and QFT-GIT, and 74% between TST and T-SPOT) than patients from high endemic countries (73% between TST and QFT-GIT, and 81% between TST and T-SPOT). By underlying disease stratification, a lower level of agreement between TST and QFT-GIT was found among AS (64%) than among JIA (77%) and RA patients (73%). Conclusions: We reaffirm the current evidence for accuracy of LTBI test done by TST and IGRA among rheumatic patients is inconsistent. Our stratified analysis suggests different screening strategies might be needed in clinical settings considering the endemic status in the patient's country of origin and the precise nature of underlying diseases.

키워드

참고문헌

  1. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001;15:335-361. https://doi.org/10.1016/S0891-5520(05)70149-5
  2. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford) 2005;44:1205-1206. https://doi.org/10.1093/rheumatology/kei103
  3. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791. https://doi.org/10.1136/ard.62.8.791
  4. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-639. https://doi.org/10.1002/acr.21641
  5. Camlar SA, Makay B, Appak O, et al. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1189-1193. https://doi.org/10.1007/s10067-011-1724-3
  6. Chang B, Park HY, Jeon K, et al. Interferon-$\gamma$ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011;30:1535-1541. https://doi.org/10.1007/s10067-011-1771-9
  7. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving $TNF{\alpha}$ inhibitors: the utility of $IFN{\gamma}$ assay. Ann Rheum Dis 2012;71:231-237. https://doi.org/10.1136/annrheumdis-2011-200489
  8. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TBendemic population. J Rheumatol 2008;35:776-781.
  9. Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. QuantiFERON-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14:R147. https://doi.org/10.1186/ar3882
  10. Hsia EC, Schluger N, Cush JJ, et al. Interferon-$\gamma$ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-2077. https://doi.org/10.1002/art.34382
  11. Klein M, Jarosova K, Forejtova S, et al. QuantiFERON TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 2013;31:111-117.
  12. Kim JH, Cho SK, Han M, et al. Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum 2013;42:424-432. https://doi.org/10.1016/j.semarthrit.2012.07.001
  13. Marques CD, Duarte AL, de Lorena VM, et al. Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis. Rheumatol Int 2009;30:57-62. https://doi.org/10.1007/s00296-009-0910-y
  14. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon $\gamma$ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783-1790. https://doi.org/10.1136/annrheumdis-2011-200408
  15. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-185. https://doi.org/10.1136/ard.2008.101857
  16. Minguez S, Latorre I, Mateo L, et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 2012;31:785-794. https://doi.org/10.1007/s10067-012-1938-z
  17. Paluch-Oles J, Magrys A, Koziol-Montewka M, Koszarny A, Majdan M. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-$\alpha$ agents. Arch Med Sci 2013;9:112-117.
  18. Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011;29:790-794.
  19. Saidenberg-Kermanac'h N, Semerano L, Naccache JM, et al. Screening for latent tuberculosis in anti-TNF-$\alpha$ candidate patients in a high tuberculosis incidence setting. Int J Tuberc Lung Dis 2012;16:1307-1314. https://doi.org/10.5588/ijtld.12.0111
  20. Scrivo R, Sauzullo I, Mengoni F, et al. Serial interferon-$\gamma$ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012;31:1567-1575. https://doi.org/10.1007/s10067-012-2049-6
  21. Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009;13:1427-1432.
  22. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-1276.
  23. Vassilopoulos D, Tsikrika S, Hatzara C, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-2108. https://doi.org/10.1128/CVI.05299-11
  24. Xie X, Chen JW, Li F, Tian J, Gao JS, Zhang D. A T-cellbased enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. Clin Exp Med 2011;11:155-161. https://doi.org/10.1007/s10238-010-0123-4
  25. Ruan Q, Zhang S, Ai J, Shao L, Zhang W. Screening of latent tuberculosis infection by interferon-$\gamma$ release assays in rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol 2016;35:417-425. https://doi.org/10.1007/s10067-014-2817-6
  26. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210-214. https://doi.org/10.7326/0003-4819-126-3-199702010-00005
  27. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21. https://doi.org/10.1164/ajrccm.159.1.9801120
  28. Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl 2014;91:41-46. https://doi.org/10.3899/jrheum.140101
  29. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-622.
  30. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-2163. https://doi.org/10.3899/jrheum.090150
  31. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-1242. https://doi.org/10.1136/ard.2002.004598

피인용 문헌

  1. Latent tuberculosis infection and non-infectious co-morbidities: Diabetes mellitus type 2, chronic kidney disease and rheumatoid arthritis vol.80, pp.suppl, 2018, https://doi.org/10.1016/j.ijid.2019.02.018
  2. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study vol.36, pp.10, 2021, https://doi.org/10.3346/jkms.2021.36.e70